Cargando…

Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis

Background: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) have been the first-line treatments for advanced or metastatic urothelial carcinoma (AMUC). However, their effects are unsatisfactory, and more drugs and regimens still need to be explored. Ob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Hong-Chen, Huang, Yan, Mu, Zhong-Yi, Lv, Hang, Xie, Qing-Peng, Wang, Kai, Hu, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974923/ https://www.ncbi.nlm.nih.gov/pubmed/32009946 http://dx.doi.org/10.3389/fphar.2019.01507

Ejemplares similares

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
por: Pei, Fajun, et al.
Publicado: (2021)

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer
por: Yang, Qian-Yu, et al.
Publicado: (2022)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
por: Liu, Xiaoyan, et al.
Publicado: (2022)

Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
por: Shi, Fenghao, et al.
Publicado: (2022)

Porcine Bladder Urothelial, Myofibroblast, and Detrusor Muscle Cells: Characterization and ATP Release
por: Cheng, Ying, et al.
Publicado: (2011)

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study
por: Wei, Yongbao, et al.
Publicado: (2023)

Update on the Treatment of Metastatic Urothelial Carcinoma
por: Bukhari, Nedal, et al.
Publicado: (2018)

Update on Chemotherapy in the Treatment of Urothelial Carcinoma
por: Costantini, Carrie, et al.
Publicado: (2011)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Cai, Hongfu, et al.
Publicado: (2021)

Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: An updated systematic review and meta-analysis
por: Zhou, Xing Qin, et al.
Publicado: (2022)

The Relationship of Pyroptosis-Related Genes, Patient Outcomes, and Tumor-Infiltrating Cells in Bladder Urothelial Carcinoma (BLCA)
por: Xie, Ruiyan, et al.
Publicado: (2022)

Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
por: Hsieh, Meng-Che, et al.
Publicado: (2016)

Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis
por: Xie, Renxian, et al.
Publicado: (2023)

Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma
por: Côté, Gabrielle, et al.
Publicado: (2023)

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma
por: Tong, Xiwen, et al.
Publicado: (2023)

Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches
por: Bambury, Richard M., et al.
Publicado: (2013)

A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer
por: Zhang, Dan, et al.
Publicado: (2019)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
por: Sun, Fengze, et al.
Publicado: (2022)

Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data
por: Fischer, Christine, et al.
Publicado: (2020)

The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
por: Cai, Changjing, et al.
Publicado: (2022)

Advances in Drug Delivery via Biodegradable Ureteral Stent for the Treatment of Upper Tract Urothelial Carcinoma
por: Shan, Hongli, et al.
Publicado: (2020)

Advances in the Management of Patients With Urothelial Carcinomas of the Bladder
por: Shah, Amishi, et al.
Publicado: (2018)

Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation
por: Sun, Xin, et al.
Publicado: (2022)

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
por: Guancial, Elizabeth A, et al.
Publicado: (2014)

Metastatic Pleural Effusion: An Unusual Presentation of Urothelial Bladder Carcinoma
por: Javed, Isma N, et al.
Publicado: (2019)

Small bowel obstruction secondary to metastatic urothelial bladder cancer
por: Wasfie, Tarik, et al.
Publicado: (2023)

Safety Profile of Nutraceuticals Rich in Coumarins: An Update
por: Heghes, Simona Codruta, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
por: Ye, Zhuo-Miao, et al.
Publicado: (2022)

Individualized antibiotic dosage regimens for patients with augmented renal clearance
por: Shi, A-Xi, et al.
Publicado: (2023)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

The Role of Brain-Derived Neurotrophic Factor in Epileptogenesis: an Update
por: Wang, Xinyi, et al.
Publicado: (2021)

The era of personalized treatments: Updates on immunotherapy within urothelial of bladder cancer
por: Wu, Zhang-Song, et al.
Publicado: (2022)

Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022)

Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma
por: Katims, Andrew B., et al.
Publicado: (2022)

First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China
por: Shen, Jian, et al.
Publicado: (2022)

Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens
por: Bundrant, Lu Ann, et al.
Publicado: (2018)

Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update
por: Lin, Yiping, et al.
Publicado: (2021)

Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia
por: Ding, Jianghua, et al.
Publicado: (2023)

Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
por: Yang, Rui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0vto2vhnl3l4ij84gs8h1allcc